Chemical Structure : XJ-4-85
货号: PC-27712Not For Human Use, Lab Use Only.
XJ-4-85 is a highly selective, covalent, allosteric phosphofructokinase-1 liver type (PFKL) activator with EC50 of 342.3 nM in substrate assays (4h), releases carnitine palmitoyltransferase 2 (CPT2) inhibitor destabilize cancer cell metabolism.
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
XJ-4-85 is a highly selective, covalent, allosteric phosphofructokinase-1 liver type (PFKL) activator with EC50 of 342.3 nM in substrate assays (4h), releases carnitine palmitoyltransferase 2 (CPT2) inhibitor destabilize cancer cell metabolism.
XJ-4-85 selectively modifies K677 in the allosteric effector site to stabilize the R-state tetramer of PFKL.
XJ-4-85 exhibits dose- and time-dependent activation of PFKL.
XJ-4-85 potently engages PFKL in HEK293T cells with IC50 of 141 nM in gel-based competitive ABPP data, but no other detectable PFK1 isoforms.
XJ-4-85 activates glycolysis across multiple cell types, induces rapid alterations in glycolytic metabolism.
XJ-4-85 (5 uM. 2h) markedly elevated intracellular FBP levels in THP-1, Jurkat, MOLM-14 and SH-SY5Y cells relative to vehicle control.
XJ-4-85 releases a selective CPT2-targeting payload, inhibits cell proliferation against B16-F10-Luc2 and MOLM-14 cells with IC50 of ~2 uM.
XJ-4-85 (10-50 mg/kg, intraperitoneal injection) inhibits melanoma tumor outgrowth in C57BL/6 mice bearing B16-F10-Luc2 tumors.
| 分子量 | 628.64 | |
| 分子式 | C31H28F4N4O4S | |
| 外观性状 | Solid | |
| 储存条件 |
|
|
| Solubility |
10 mM in DMSO |
|
1. Jiang X, et al. A covalent PFKL activator suppresses tumor growth. Nat Chem Biol. 2026 Aug 5. doi: 10.1038/s41589-026-02289-9.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright